FDA Encourages Sponsors Of Hypertension Drugs To Promote Their Cardiovascular Benefits
This article was originally published in The Pink Sheet Daily
Final guidance allowing class-wide outcomes claims includes suggested language for both advertising and labeling.
You may also be interested in...
Lamictal XR Monotherapy: Will Ex-U.S. Data Invalidate Historical Comparison?
FDA reviewers cite issues with the study design GSK used in its sNDA, but still find evidence of efficacy for partial seizures.
Restanza Superiority Trials Intended To Avoid Non-Inferiority "Quagmire"
Advanced Life Sciences CEO Michael Flavin decided a pair of superiority trials was the best way to prove the efficacy of the company’s Restanza in community-acquired bacterial pneumonia, given the "stalemate" at FDA regarding the use of non-inferiority trials in antibiotics.
Hypertension DTC Ads Should Attribute Benefits To All Blood Pressure Drugs
Antihypertensive drug direct-to-consumer advertisements should include a statement that all drugs that lower blood pressure reduce risk of serious cardiovascular outcomes, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said April 27